KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Neogenomics (NEO) Debt to Equity: 2009-2020

Historic Debt to Equity for Neogenomics (NEO) over the last 7 years, with Mar 2020 value amounting to $0.19.

  • Neogenomics' Debt to Equity fell 34.69% to $0.19 in Q1 2020 from the same period last year, while for Mar 2020 it was $0.19, marking a year-over-year decrease of 34.69%. This contributed to the annual value of $0.19 for FY2019, which is 36.14% down from last year.
  • Per Neogenomics' latest filing, its Debt to Equity stood at $0.19 for Q1 2020, which was down 0.80% from $0.19 recorded in Q4 2019.
  • In the past 5 years, Neogenomics' Debt to Equity ranged from a high of $0.60 in Q2 2018 and a low of $0.19 during Q1 2020.
  • In the last 3 years, Neogenomics' Debt to Equity had a median value of $0.29 in 2019 and averaged $0.30.
  • In the last 5 years, Neogenomics' Debt to Equity skyrocketed by 80.59% in 2017 and then tumbled by 66.08% in 2019.
  • Quarterly analysis of 5 years shows Neogenomics' Debt to Equity stood at $0.46 in 2016, then dropped by 10.12% to $0.41 in 2017, then decreased by 26.98% to $0.30 in 2018, then tumbled by 36.14% to $0.19 in 2019, then slumped by 34.69% to $0.19 in 2020.
  • Its Debt to Equity was $0.19 in Q1 2020, compared to $0.19 in Q4 2019 and $0.20 in Q3 2019.